- Rizatriptan
-
- $1.00 / 1g
-
2026-01-05
- CAS:144034-80-0
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Rizatriptan USP/EP/BP
-
- $1.10 / 1g
-
2025-11-18
- CAS:144034-80-0
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
- Rizatriptan
-
- $0.00 / 10mg
-
2025-09-25
- CAS:144034-80-0
- Min. Order: 10mg
- Purity: 0.98
- Supply Ability: 10g
|
| | Rizatriptan Basic information |
| Product Name: | Rizatriptan | | Synonyms: | n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indole-3-ethanamine;n,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethanamine;RIZATRIPTAN;diMethyl({2-[5-(1H-1,2,4-triazol-1-ylMethyl)-1H-indol-3-yl]ethyl})aMine;2-(5-((1H-1,2,4-Triazol-1-yl)Methyl)-1H-indol-3-yl)-N,N-diMethylethanaMine;1H-Indole-3-ethanaMine,N,N-diMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-;Rizatriptan###144034-80-0;2-(5-((1H-1,2,4-Triazol-1-yl) | | CAS: | 144034-80-0 | | MF: | C15H19N5 | | MW: | 269.34 | | EINECS: | | | Product Categories: | NORVASC;Other APIs | | Mol File: | 144034-80-0.mol |  |
| | Rizatriptan Chemical Properties |
| Melting point | 178-180°C | | Boiling point | 504.8±60.0 °C(Predicted) | | density | 1.21±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | pka | 16.98±0.30(Predicted) | | Water Solubility | 42 mg/mL | | InChI | InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 | | InChIKey | ULFRLSNUDGIQQP-UHFFFAOYSA-N | | SMILES | N1C2=C(C=C(CN3C=NC=N3)C=C2)C(CCN(C)C)=C1 | | CAS DataBase Reference | 144034-80-0(CAS DataBase Reference) | | EPA Substance Registry System | Acetonitrile, 2,2-dibromo-2-chloro- (144034-80-0) |
| | Rizatriptan Usage And Synthesis |
| Uses | Rizatriptan is reported to be a very effective acute migraine drug. It is reported to display high agonist activity at mainly the serotonin 5-HT1B and 5-HT1D receptor subtypes. | | Uses | Ca channel blocker | | Definition | ChEBI: Rizatriptan is a member of tryptamines. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is functionally related to a N,N-dimethyltryptamine. | | Brand name | Maxalt (Merck). | | General Description | Rizatriptan, approved in 1998, is a fast-acting triptan becauseof its moderate lipophilicity yet has a very shortelimination half-life similar to sumatriptan (i.e., like sumatriptan,it is mainly metabolized by MAO-A). The only advantagesof this drug when compared with sumatriptan arethat it has a slightly faster onset and that it has an orallydisintegrating tablet formulation which can be taken withoutwater. | | Clinical Use | 5HT1
receptor agonist:
Acute treatment of migraine | | Drug interactions | Potentially hazardous interactions with other drugs
Antidepressants: increased risk of CNS excitation
with citalopram - avoid; risk of CNS toxicity
with MAOIs, moclobemide and linezolid - avoid
for 2 weeks after discontinuation of MAOI and
moclobemide; possibly increased serotonergic
effects with duloxetine and venlafaxine; increased
serotonergic effects with St John’s wort - avoid.
Dapoxetine: possible increased risk of serotonergic
effects - avoid for 2 weeks after stopping 5HT1
agonists.
Ergot alkaloids: increased risk of vasospasm - avoid.
Propranolol: rizatriptan levels increased, reduce dose
of rizatriptan to 5 mg (max 10 mg in 24 hours). | | Metabolism | The main route of rizatriptan metabolism is via oxidative
deamination by monoamine oxidase-A (MAO-A)
to the indole acetic acid metabolite, which is not
pharmacologically active. N-monodesmethyl-rizatriptan,
a metabolite with activity similar to that of parent
compound, is formed to a minor degree, but does not
contribute significantly to the pharmacodynamic activity
of rizatriptan.
Less than 1% is excreted in the urine as active
N-monodesmethyl metabolite. |
| | Rizatriptan Preparation Products And Raw materials |
|